Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance

Human Pathology

Volumn 44, Issue 5, 2013, Pages 777-785

  Hetland, Thea Eline ^a   Nymoen, Dag Andre ^a   Holth, Arild ^a   Brusegard, Kjersti ^a   Flørenes, Vivi Ann ^a   Kærn, Janne ^a   Tropé, Claes G ^a,b   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Aurora kinases; Chemotherapy response; Effusions; Ovarian carcinoma; Survival; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; BETA TUBULIN; BETA TUBULIN CLASS 3; CARBOPLATIN; CISPLATIN; KI 67 ANTIGEN; MESSENGER RNA; PACLITAXEL; PLATINUM; PROTEIN KINASE B; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM EXUDATE; PLEURA EFFUSION; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR; TREATMENT RESPONSE;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TUBULIN;

EID: 84876482354     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.08.002     Document Type: Article

References (32)

1. A.P. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary Int J Gynaecol Obstet 83 Suppl 1 2003 135 166 (Pubitemid 39658498)
2. E. Salom, Z. Almeida, and R. Mirhashemi Management of recurrent ovarian cancer: evidence based decisions Curr Opin Oncol 14 2002 519 527
3. H.T. Ma, and R.Y. Poon How protein kinases co-ordinate mitosis in animal cells Biochem J 435 2011 17 31
4. T. Marumoto, D. Zhang, and H. Saya Aurora-A - a guardian of poles Nat Rev Cancer 5 2005 42 50 (Pubitemid 40052324)
5. T.M. Gritsko, D. Coppola, and J.E. Paciga Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer Clin Cancer Res 9 2003 1420 1426 (Pubitemid 36418396)
6. G. Yang, B. Chang, and F. Yang Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2 Clin Cancer Res 16 2010 3171 3181
7. A.A. Kulkarni, M. Loddo, and E. Leo DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma Clin Cancer Res 13 2007 6153 6161 (Pubitemid 350075075)
8. S. Anand, S. Penrhyn-Lowe, and A.R. Venkitaraman AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol Cancer Cell 3 2003 51 62 (Pubitemid 37443890)
9. S. Lassmann, Y. Shen, and U. Jütting Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy Clin Cancer Res 13 2007 4083 4091 (Pubitemid 47105969)
10. H. Lassus, S. Staff, A. Leminen, J. Isola, and R. Butzow Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma Gynecol Oncol 120 2011 11 17
11. C.N. Landen Jr., Y.G. Lin, and A. Immaneni Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients Clin Cancer Res 13 2007 4098 4104 (Pubitemid 47105971)
12. M. Mendiola, J. Barriuso, and A. Mariño-Enríquez Aurora kinases as prognostic biomarkers in ovarian carcinoma Hum Pathol 40 2009 631 638
13. G. Vader, and S.M. Lens The Aurora kinase family in cell division and cancer Biochim Biophys Acta 1786 2008 60 72
14. Y.J. Chen, C.M. Chen, and N.F. Twu Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients Virchows Arch 455 2009 431 440
15. S. Beussel, A. Hasenburg, L. Bogatyreva, D. Hauschke, M. Werner, and S. Lassmann Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma J Clin Pathol 65 2012 29 35
16. A.A. Dar, L.W. Goff, S. Majid, J. Berlin, and W. El-Rifai Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 9 2010 268 278
17. H. Katayama, and S. Sen Aurora kinase inhibitors as anticancer molecules Biochim Biophys Acta 1799 2010 829 839
18. M. Köbel, S.E. Kalloger, and N. Boyd Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 2008 e232
19. B. Davidson Biological characteristics of cancers involving the serosal cavities Crit Rev Oncog 13 2007 189 227 (Pubitemid 351239093)
20. B. Davidson, S. Nielsen, and J. Christensen The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells Am J Surg Pathol 25 2001 1405 1412 (Pubitemid 33022056)
21. T.E. Hetland, D.A. Nymoen, and E. Emilsen MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival Gynecol Oncol 126 2012 460 465
22. J.T. Thigpen, J.A. Blessing, H. Ball, S.J. Hummel, and R.J. Barrett Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753 (Pubitemid 24349373)
23. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
24. M. Bunkholt Elstrand, H.P. Dong, and E. degaard Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma Hum Pathol 41 2010 794 804
25. L. Kleinberg, H.P. Dong, and A. Holth Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma Hum Pathol 40 2009 795 806
26. L. Kleinberg, V.A. Flørenes, and I. Silins Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma Cancer 109 2007 228 238 (Pubitemid 46106237)
27. T.E. Hetland, E. Hellesylt, V.A. Flørenes, C. Tropé, B. Davidson, and J. Kærn Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance Hum Pathol 42 2011 1019 1026
28. L. Kleinberg, M. Pradhan, C.G. Trope', J.M. Nesland, D. Davidson, and B. Risberg Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors Diagn Cytopathol 36 2008 637 644
29. S.M. Campos, and S. Ghosh A current review of targeted therapeutics for ovarian cancer J Oncol 2010 2010 149362
30. S.M. Lens, E.E. Voest, and R.H. Medema Shared and separate functions of polo-like kinases and aurora kinases in cancer Nat Rev Cancer 10 2010 825 841
31. K. Das, P.D. Lorena, and L.K. Ng Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers Pathology 42 2010 540 546
32. M. Köbel, D. Turbin, S.E. Kalloger, D. Gao, D.G. Huntsman, and C.B. Gilks Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites Int J Gynecol Pathol 30 2011 366 371